FDA halts Aardvark Therapeutics Prader-Willi drug trials
The FDA placed a clinical hold on Aardvark Therapeutics' Prader-Willi drug after heart-related side effects. Shares fell 14% as late-stage trials were halted.
Xurve View
Insights:
Xurve View
AARDVARK THERAPEUTICS INC shares fell 14% in after-hours trading after the United States Food and Drug Administration halted all late-stage trials for its lead drug candidate. The regulator placed a full clinical hold on ARD-101, an oral treatment for extreme hunger in Prader-Willi syndrome patients. The move stops development of a key asset that Aardvark previously paused due to safety concerns in healthy volunteers.
